SARS-COV-2 antibodies after booster vaccination. Identification of subgroups with poor response.
Rev Clin Esp (Barc)
; 223(6): 379-382, 2023.
Article
in English
| MEDLINE | ID: covidwho-2307378
ABSTRACT
OBJECTIVE:
To determine which patients within the high-risk group are most likely to have insufficient post-vaccination immunity.METHODS:
Determination of IgG titers against SARS-CoV-2 after the booster dose. Vaccine response was categorized as negative (IgG titersâ¯<â¯34â¯BAU/ml), indeterminate (titers 34-259â¯BAU/ml) or positive (≥260â¯BAU/ml).RESULTS:
765 patients were included (31.25% of those vaccinated). 54 (7.1%) on treatment with biologics, 90 (11.8%) with hematologic disease, 299 (39.1%) with oncologic pathology, 304 (39.7%) with solid organ transplant and 18 (2.4%) with immunosuppression for other reasons. 74 patients (9.7%) had negative serology and 45 (5.9%) had indeterminate titers. By diagnostic group, the patients with the highest proportion of negative or indeterminate serology were patients with biologic treatment (55.6%, mainly at expense of antiCD20), hematologic (35.4%) and transplant patients (17.8%, mainly lung and kidney). Oncology and other immunosuppressed patients had a favorable response to vaccination.CONCLUSION:
Patients treated with antiCD20 drugs, hematologic patients and transplanted patients (mainly lung and kidney) have a higher risk of not achieving post-vaccination immunity. It is essential to identify them in order to individualize and optimize their management.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Case report
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Rev Clin Esp (Barc)
Year:
2023
Document Type:
Article
Affiliation country:
J.rceng.2023.04.008
Similar
MEDLINE
...
LILACS
LIS